DUSP1 and cancer: When evaluating combination treatment approaches, assessing safety and efficacy of DUSP1 alone and in combination with standard of care oncologic approaches and coordinating the timing and delivery of DUSP1-targeted inhibitors with other cancer treatments, will be vital to achieving maximum therapeutic potential.